News
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Movers
Stifel Maintains Hold on Atara Biotherapeutics, Lowers Price Target to $2.3
1 Apr 24
News, Price Target, Analyst Ratings
Atara Biotherapeutics Q4 EPS $(0.56) Misses $(0.48) Estimate, Sales $4.25M Miss $11.55M Estimate
28 Mar 24
Earnings, Earnings Misses, News
Atara Biotherapeutics: Q4 Earnings Insights
28 Mar 24
Earnings
12 Health Care Stocks Moving In Monday's After-Market Session
18 Mar 24
Movers
12 Health Care Stocks Moving In Friday's After-Market Session
8 Mar 24
Movers
12 Health Care Stocks Moving In Wednesday's After-Market Session
6 Mar 24
Movers
Atara Biotherapeutics Receives FDA Clearance Of IND Application In Lupus Nephritis For ATA3219
29 Feb 24
Biotech, News, FDA, General
Atara Biotherapeutics Announces Submission Of Investigational New Drug Application For ATA3219 For Treatment Of Lupus Nephritis
14 Feb 24
Biotech, News, FDA, General
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
5 Feb 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Friday's After-Market Session
2 Feb 24
Movers
12 Health Care Stocks Moving In Friday's Intraday Session
2 Feb 24
Movers
Reported Late Wednesday, Atara Biotherapeutics And Pierre Fabre Laboratories Announced The Publication Of Phase 3 ALLELE Tab-Cel® Data In The Lancet Oncology
1 Feb 24
News
Press releases
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
Press Releases
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
28 Mar 24
Press Releases
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
29 Feb 24
Press Releases
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
28 Feb 24
Press Releases
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
14 Feb 24
Press Releases
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
31 Jan 24
Press Releases